English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/142691
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis

AutorTojo, Rafael; Suárez, Ana; García Clemente, Marta; González de los Reyes-Gavilán, Clara ; Margolles Barros, Abelardo ; Gueimonde Fernández, Miguel ; Ruas-Madiedo, Patricia
Fecha de publicación7-nov-2014
EditorBaishideng Publishing Group
CitaciónWorld Journal of Gastroenterology 20: 15163-15176 (2014)
ResumenAll rights reserved. The pool of microbes inhabiting our body is known as >microbiota> and their collective genomes as >microbiome>. The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g. , allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies. © 2014 Baishideng Publishing Group Inc.
Versión del editorhttps://doi.org/10.3748/wjg.v20.i41.15163
URIhttp://hdl.handle.net/10261/142691
DOI10.3748/wjg.v20.i41.15163
Identificadoresissn: 2219-2840
Aparece en las colecciones: (IPLA) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.